Evidence map›Paper›PMID 24193353›Full record

SynthesisDigestive diseases and sciences2014

Measures to reduce mother-to-child transmission of Hepatitis B virus in China: a meta-analysis.

Hua Xu, Teng Zeng, Jun-Ying Liu, Yu Lei, Shan Zhong, Yun-Jian Sheng, Zhi Zhou, Hong Ren

Registry-linked trialAbstract readMeta-AnalysisReview
PubMed Publisher
In one paragraph

Synthesis in Digestive diseases and sciences, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02995005 (Prevention of Mother-to-child Transmission of Hepatitis B Virus), which is not on this map. Cited by 15 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02995005 phase1 / phase2completednot on this mapstarted 2018, after this paper: background citation

Prevention of Mother-to-child Transmission of Hepatitis B Virus: a One Arm, Open Label Intervention Study to Estimate the Optimal Timing of Tenofovir (TDF) in Pregnancy

TypeinterventionalSponsorJohns Hopkins Bloomberg School of Public HealthRan2018 to 2023Enrolled98ConditionsHepatitis BArmsTenofovir Disoproxil Fumarate
3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Viral hepatitis vaccination during pregnancy.Human vaccines & immunotherapeutics · 2016
    Review
  14. Vertical transmission of hepatitis B virus: challenges and solutions.International journal of women's health · 2014
    Review
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Hua XuThe Second College of Clinical Medicine, The Second Affiliated Hospital of Chongqing Medical University, 74 Lingjiang Road, Central District, Chongqing, 400010, China, xuhua0605@126.com.
Teng Zeng
Jun-Ying Liu
Yu Lei
Shan Zhong
Yun-Jian Sheng
Zhi Zhou
Hong Ren

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMother-to-child transmission (MTCT) is the main mode of spread of hepatitis B virus (HBV) in China. We performed a meta-analysis to compare the effects of three measures for prevention of MTCT.

methodsA meta-analysis was performed on randomized controlled trials and non-randomized studies comparing the index of MTCT among five groups of pregnant women: hepatitis B immunoglobulin (HBIG) administration, antiviral treatment, placebo, elective caesarean section, and vaginal delivery.

resultsCompared with the control group, the incidence of HBV intrauterine infection (RR = 0.42, 95 % CI 0.27-0.64, P < 0.0001) and the number of chronic hepatitis B (CHB) infants (RR = 0.44, 95 % CI 0.32-0.61, P < 0.00001) were lower in the HBIG administration group. In the antiviral treatment group, serum HBV DNA levels were lower (MD = -4.01, 95 % CI -5.07 to -2.94, P < 0.00001) at the time of delivery, and normalization of ALT levels was better (RR = 1.11, 95 % CI 1.06-1.17, P < 0.0001). Infant serum HBsAg positivity (RR = 0.45, 95 % CI 0.22-0.91, P = 0.03) and incidence of infant HBV transmission RR = 0.06, 95 % CI 0.01-0.24, P < 0.0001) were reduced in antiviral the treatment group. Infant serum anti-HBs positivity at birth (RR = 1.24, 95 % CI 0.89-1.74, P = 0.2) or at 6-7 months (RR = 0.98, 95 % CI 0.86-1.11, P = 0.73) was not significantly different between the caesarean section and vaginal delivery groups. The incidence of infant CHB infection may have been higher in the vaginal delivery group (RR = 2.20, 95 % CI 1.02-4.74, P = 0.04).

conclusionsAdministration of HBIG or antiviral therapy to HBV carrier mothers during pregnancy is effective in reducing MTCT.

Indexed as

Cesarean SectionAdultAntiviral AgentsChinaChi-Square DistributionElective Surgical ProceduresFemaleHepatitis B, ChronicHepatitis B VaccinesHumansImmunoglobulinsIncidenceInfant, NewbornInfectious Disease Transmission, VerticalOdds RatioPregnancyAntiviral Agentshepatitis B hyperimmune globulinHepatitis B VaccinesImmunoglobulins

Identifiers

PMID24193353

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.